Eli Lilly and Company’s investigational drug, retatrutide, a pioneering triple hormone receptor agonist, has demonstrated an average weight loss of…
Read More

Eli Lilly and Company’s investigational drug, retatrutide, a pioneering triple hormone receptor agonist, has demonstrated an average weight loss of…
Read More
Findings presented at the 33rd European Congress on Obesity in Istanbul, Turkey, on May 15th, have provided a crucial comparative…
Read More